Clinical and laboratory characteristics of invasive infections due to methicillin-resistant staphylococcus aureus isolates demonstrating a vancomycin mic of 2 micrograms per milliliter: Lack of effect of heteroresistant vancomycin-intermediate S. aureus phenotype

Journal of Clinical Microbiology

Volumn 49, Issue 4, 2011, Pages 1583-1587

  Satola, S W ^a,b   Lessa, F C ^c   Ray, S M ^a   Bulens, S N ^c,d   Lynfield, R ^e   Schaffner, W ^f   Dumyati, G ^g   Nadle, J ^h   Patel, J B ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^d ATLANTA RESEARCH AND EDUCATION FOUNDATION   (United States)

^e MINNESOTA DEPARTMENT OF HEALTH   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF ROCHESTER   (United States)

^h CALIFORNIA EMERGING INFECTIONS PROGRAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; RIFAMPICIN; VANCOMYCIN;

ABSCESS; ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHILD; COMMUNICABLE DISEASE; CONTROLLED STUDY; ENDOCARDITIS; FEMALE; HOSPITAL PATIENT; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; OSTEOMYELITIS; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; SCHOOL CHILD; SEPSIS; STAPHYLOCOCCUS AUREUS; THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RECURRENCE; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN RESISTANCE; YOUNG ADULT;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 79953883548     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01719-10     Document Type: Article

References (25)

1. Adam, H. J., et al. 2009. Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in Canada: Results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006. Antimicrob. Agents Chemother. 54:945-949.
2. Charles, P. G., P. B. Ward, P. D. Johnson, B. P. Howden, and M. L. Grayson. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451. (Pubitemid 38200128)
3. Clinical and Laboratory Standards Institute/NCCLS. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 8th ed. Approved standard M7-A8. CLSI, Wayne, PA.
4. Clinical and Laboratory Standards Institute/NCCLS. 2009. Performance standards for antimicrobial disk susceptibility tests, 10th ed. Approved standard M2-A10. CLSI, Wayne, PA.
5. Horne, K. C., et al. 2009. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob. Agents Chemother. 53:3447-3452.
6. Howden, B. P., et al. 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521-528. (Pubitemid 38250962)
7. Hsu, D. I., et al. 2008. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents 32:378-385.
8. Kirst, H. A., D. G. Thompson, and T. I. Nicas. 1998. Historical yearly usage of vancomycin. Antimicrob. Agents Chemother. 42:1303-1304.
9. Klevens, R. M., et al. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771. (Pubitemid 47598444)
10. Limbago, B., et al. 2009. Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease: A population-based analysis. J. Clin. Microbiol. 47:1344-1351.
11. Liu, C., and H. F. Chambers. 2003. Staphylococcus aureus with heterogeneous resistance to vancomycin: Epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47: 3040-3045. (Pubitemid 37229554)
12. Maclayton, D. O., K. J. Suda, K. A. Coval, C. B. York, and K. W. Garey. 2006. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin. Ther. 28:1208-1216. (Pubitemid 44374748)
13. Maor, Y., et al. 2009. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis. 199:619-624.
14. McDougal, L. K., et al. 2003. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: Establishing a national database. J. Clin. Microbiol. 41:5113-5120. (Pubitemid 37429924)
15. Musta, A. C., et al. 2009. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: Trends over 11 years. J. Clin. Microbiol. 47:1640-1644.
16. Rybak, M. J., et al. 2008. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J. Clin. Microbiol. 46:2950-2954.
17. Sakoulas, G., R. C. Moellering, Jr., and G. M. Eliopoulos. 2006. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin. Infect. Dis. 42(Suppl. 1):S40-S50. (Pubitemid 41832064)
18. Sakoulas, G., et al. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402. (Pubitemid 38747480)
19. Satola, S. W., A. M. Caliendo, M. M. Farley, J. B. Patel, and E. M. Burd. 2009. Lack of heteroresistance among Staphylococcus aureus isolates with vancomycin MICs of 2 micrograms per milliliter by automated testing. J. Clin. Microbiol. 47:2680-2681.
20. Satola, S. W., M. M. Farley, K. F. Anderson, and J. B. Patel. 2011. Comparison of detection methods for heteroresistant vancomycin intermediate Staphylococcus aureus, with the population analysis profile as the reference method. J. Clin. Microbiol. 49:177-183.
21. Steinkraus, G., R. White, and L. Friedrich. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycinsusceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60:788-794. (Pubitemid 47434257)
22. Swenson, J. M., et al. 2009. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J. Clin. Microbiol. 47:2013-2017.
23. Tenover, F. C., et al. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 36:1020-1027. (Pubitemid 28146289)
24. Tenover, F. C., and R. C. Moellering, Jr. 2007. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44:1208-1215. (Pubitemid 46651246)
25. Wang, G., J. F. Hindler, K. W. Ward, and D. A. Bruckner. 2006. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44:3883-3886. (Pubitemid 44737223)